Literature DB >> 25562748

Immunohistochemical assessment of PTEN in vulvar cancer: best practices for tissue staining, evaluation, and clinical association.

A M Lavorato-Rocha1, L G Anjos1, I W Cunha1, J Vassallo1, F A Soares1, R M Rocha2.   

Abstract

BACKGROUND: Pten encodes a well-characterized protein that is important in several cancers due to its tumor suppressor function. Yet, the detection and evaluation of PTEN by immunohistochemistry (IHC) for clinical practice have not been standardized. Thus, in this study, we performed a literature review of protocols for PTEN assessment by IHC and the possible differences in evaluation, based on our experience with vulvar carcinomas. Also, we report some of our most recent findings regarding the clinical impact of PTEN in this type of tumor.
METHODS: In total, 150 FFPE vulvar carcinoma samples in a tissue microarray were examined by IHC with regard to PTEN, PI3K, AKT, and mTOR. All evaluations were performed by slide digitalization and quantification using APERIO ImageScope software. All measurements were converted into HScore values for the statistical analysis.
RESULTS: Sharp and specific PTEN expression was observed in the nuclei and cytoplasmic compartments. Its HScore values ranged from 3.5 to 226, with a median of 92.5. mTOR expression was robust in all cases (mean HScore=248.1). AKT and PI3K had median HScore values of 200.5 and 156.5, respectively. In addition, PTEN expression was associated with higher rates of patient survival.
CONCLUSION: The preanalytical step is the first issue in the immunohistochemical evaluation of PTEN. With regard to the analytical procedure, the antigen retrieval step yielded better stains for protocols with high-pH buffers, and antibody clone 6H2.1 effected the most reliable results. PTEN is a good prognostic marker for vulvar cancer, correlating with higher rates of patient survival. Our data underscore the importance of technical standardization to ensure more reliable and reproducible evaluation of PTEN in clinical practice.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; PTEN; Protocol; Vulvar cancer

Mesh:

Substances:

Year:  2015        PMID: 25562748     DOI: 10.1016/j.ymeth.2014.12.017

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  6 in total

1.  Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.

Authors:  Iván Roa; Gonzalo de Toro; Fernanda Fernández; Anakaren Game; Sergio Muñoz; Xabier de Aretxabala; Milind Javle
Journal:  Diagn Pathol       Date:  2015-08-21       Impact factor: 2.644

2.  Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth.

Authors:  Min Wang; Xin Ge; Jitai Zheng; Dongmei Li; Xue Liu; Lin Wang; Chengfei Jiang; Zhumei Shi; Lianju Qin; Jiayin Liu; Hushan Yang; Ling-Zhi Liu; Jun He; Linlin Zhen; Bing-Hua Jiang
Journal:  Oncotarget       Date:  2016-04-05

3.  S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transition.

Authors:  Tian Tian; Xukun Li; Zhen Hua; Jianlin Ma; Xiaowei Wu; Zhihua Liu; Hongyan Chen; Zhumei Cui
Journal:  Oncotarget       Date:  2017-04-11

4.  Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Bo Wang; Mengyan Li; Anna Su; Yongmei Gao; Yan Shi; Chao Li; Wenying Liu; Liping Su; Wan Li; Yuqing Ma
Journal:  Anal Cell Pathol (Amst)       Date:  2022-08-31       Impact factor: 4.133

5.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

6.  Chronic saponin treatment attenuates damage to the pancreas in chronic alcohol-treated diabetic rats.

Authors:  Mi Ran Choi; Su Min Kwak; Sol Hee Bang; Jo-Eun Jeong; Dai-Jin Kim
Journal:  J Ginseng Res       Date:  2016-10-05       Impact factor: 6.060

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.